610
Views
7
CrossRef citations to date
0
Altmetric
Author's View

Tumor immune escape in acute myeloid leukemia

Class II-associated invariant chain peptide expression as result of deficient antigen presentation

, , , &
Pages 211-213 | Published online: 01 Mar 2012

References

  • van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, Ossenkoppele GJ, et al. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res 2011; 71:2507 - 17; http://dx.doi.org/10.1158/0008-5472.CAN-10-3689; PMID: 21310823
  • Chamuleau ME, Souwer Y, van Ham SM, Zevenbergen A, Westers TM, Berkhof J, et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004; 64:5546 - 50; http://dx.doi.org/10.1158/0008-5472.CAN-04-1350; PMID: 15313888
  • Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997; 94:6886 - 91; http://dx.doi.org/10.1073/pnas.94.13.6886; PMID: 9192661
  • Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J 2008; 27:1 - 5; http://dx.doi.org/10.1038/sj.emboj.7601945; PMID: 18046453
  • van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, et al. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother 2010; 59:1825 - 38; http://dx.doi.org/10.1007/s00262-010-0908-z; PMID: 20820776
  • van Luijn MM, Westers TM, Chamuleau ME, van Ham SM, Ossenkoppele GJ, van de Loosdrecht AA. Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia. Am J Pathol 2011; 179:2157 - 61; http://dx.doi.org/10.1016/j.ajpath.2011.07.027; PMID: 21907692
  • Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296 - 306; http://dx.doi.org/10.1038/nri1592; PMID: 15803149
  • Urba WJ, Longo DL. Redirecting T cells. N Engl J Med 2011; 365:754 - 7; http://dx.doi.org/10.1056/NEJMe1106965; PMID: 21830939
  • van den Ancker W, van Luijn MM, Ruben JM, Westers TM, Bontkes HJ, Ossenkoppele GJ, et al. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. Cancer Immunol Immunother 2011; 60:37 - 47; http://dx.doi.org/10.1007/s00262-010-0917-y; PMID: 20859626
  • Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008; 68:9601 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-07-5270; PMID: 19047136